Barrington raised the firm’s price target on Option Care Health (OPCH) to $33 from $32 and keeps an Outperform rating on the shares. The company provided a preliminary look at its Q4 and gave a better than expected outlook for fiscal 2025, the analyst tells investors in a research note. The firm suspects Option Cares financial guidance will bolster investor confidence. While it continues to have concerns regarding the biosimilar competition issue, Barrington is “breathing a sigh of relief that the company will be able to absorb the Stelara-related hit” and still likely show adjusted EBITDA growth in fiscal 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OPCH:
- BofA upgrades Option Care Health to Buy on earnings visibility
- Option Care Health upgraded to Buy from Neutral at BofA
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Option Care Health Announces Strong Growth and Share Repurchase
- Option Care Health reports preliminary Q4 adjusted EPS 42c-45c, consensus 35c